Pancreatic Cancer
Conditions
Brief summary
Gemcitabine-based chemotherapy or combination with FOLFIRINOX is the leading treatment of pancreatic cancer. However, the overall response rate of pancreatic cancer to gemcitabine is less than 20%. Resistance to gemcitabine is the most important reason. There is an urgent need to develop new combination therapies to improve the efficiency of chemotherapy, avoid toxicity limitations, and improve the overall prognosis of pancreatic cancer. At present, it has been found that canagliflozin can reduce the expression level of PD-L1 in pancreatic cancer and restore the vitality of CD8+ T cells. Canagliflozin combined with gemcitabine may improve the efficiency of chemotherapy.
Interventions
DRUGCanagliflozin and Gemcitabine
on the first, 8th and 15th day of treatment, patients were given intravenous drip of 1000mg/m2 gemcitabine, and 21 days was a course of treatment, lasting for 6 courses. Take 400mg canagliflozin orally every day, and continue to use it until the end of chemotherapy. According to the patient's tolerance to disulfiram, the dose of canagliflozin can be re-evaluated during the treatment, and the highest dose is 125mg per day. The clinical symptoms, signs and adverse reactions of patients were observed, and the treatment effect of patients was evaluated after two consecutive cycles with 4 weeks as a cycle
DRUGGemcitabine
on the first, 8th and 15th day of treatment, patients were given 1000mg/m2 gemcitabine intravenously, and 21 days was a course of treatment, lasting for 6 courses.
Sponsors
College of Pharmaceutical Sciences at Zhejiang University
The Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University
Zhang Xiaofeng,MD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Inclusion criteria: # Age ≥18 years old; #Metastatic or unresectable pancreatic cancer is confirmed through histology or cytology; # Estimated survival time \> 3 months; # Without any chemotherapy treatment or more than one month from the end of the last chemotherapy course; #ECOG physical status score 0-2; 2.
Exclusion criteria
# patients who had allergic reaction to therapeutic drugs; # patients with other types of cancer; # Patients with severe diseases of heart, liver, kidney, etc.; (4) gastrointestinal dysfunction or unable to oral medication. 3. Shedding/eliminating criteria: exiting in the midway; Lost to follow-up during the follow-up period; Treatment was not continued according to the treatment protocol.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation the clinical complete response (CR) at 6 weeks intervals | 18 weeks | The tumor lesion in our patient completely resolved and lasted for ≥4 weeks, and no new lesion appeared |
| Evaluation the clinical partial response (PR) at 6 weeks intervals | 18 weeks | the overall reduction in the longest diameter of the tumor focus is \> 50% and it can be maintained for at least 4 weeks, with no new focus emerging |
| Evaluation the clinical stable disease (SD) at 6 weeks intervals | 18 weeks | the overall reduction or increase of the longest diameter of the tumor lesion is \< 50% or \< 25%, and the duration is \> 4 weeks; no new lesion appears |
| Evaluation the clinical disease progression (PD) at 6 weeks intervals | 18 weeks | the combined increase in the longest diameter of the tumor lesion is ≥25%, or a new lesion appears |
Countries
China
Contacts
Primary ContactHongzhang Shen
Backup ContactXiaofeng Zhang
Outcome results
None listed